An era of acquisitions had left this company with a complex product portfolio. They needed to shift focus to organic growth.

This was a considerable challenge in the undifferentiated market of pharmaceutical generics. We helped them to explore the evolution of the category. In this process we discovered the emerging needs of patients and healthcare professionals. Many of these needs were currently unmet. We identified seven opportunity platforms. Each maximised global economies of scale without sacrificing local competitiveness. This generated a robust innovation pipeline of future product and service launches.

Together we developed a growth strategy that propelled them ahead of the competition. This unlocked five years of sustained growth